Skip to content

Protagonist Therapeutics

US · PTGX #1570 by market cap Listed 2016
140.92 +2.23 +1.61%
Live - 5344 symbols - heartbeat 365s ago · 2026-10-08 04:39
Pre-market 141.00 +0.06%
After-hours 140.92 0.00%
Market cap
9.12B
P/B
10.84
EPS
-2.05
Reader sentiment Are you bullish or bearish on PTGX?

Anonymous reader poll. Unscientific, not investment advice.

Recent news

  • Rating change
    H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $170
    Market Newswire · 2026/8/31
  • Rating change
    Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $173
    Market Newswire · 2026/8/31
  • Rating change
    TD Cowen Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $155
    Market Newswire · 2026/7/22
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $149 to $182
    Market Newswire · 2026/9/1
  • Protagonist Therapeutics(PTGX.US) Officer Sells US$8.31 Million in Common Stock
    Market Newswire · 2026/10/3
  • Form 144 | Protagonist Therapeutics(PTGX.US) Officer Proposes to Sell 8.26 Million in Common Stocks
    Market Newswire · 2026/10/1
  • Rating change
    BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $178
    Market Newswire · 2026/8/17
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $167 to $186
    Market Newswire · 2026/8/11
  • Rating change
    J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $149
    Market Newswire · 2026/9/1
  • Truist Financial Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating
    Market Newswire · 2026/9/2
  • Rating change
    Goldman Sachs Upgrades Protagonist Therapeutics(PTGX.US) to Buy Rating, Raises Target Price to $186
    Market Newswire · 2026/8/10
  • Rating change
    Wedbush Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $173
    Market Newswire · 2026/8/10
  • Rating change
    A Quick Look at Today's Ratings for Protagonist Therapeutics(PTGX.US), With a Forecast Between $153 to $175
    Market Newswire · 2026/8/7
  • Rating change
    H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $170
    Market Newswire · 2026/9/1
  • Protagonist Therapeutics(PTGX.US) Officer Sells US$18.24 Million in Common Stock
    Market Newswire · 2026/9/11
  • Citi Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $182
    Market Newswire · 2026/9/10
  • Rating change
    Goldman Sachs Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $186
    Market Newswire · 2026/9/1
  • Rating change
    H.C. Wainwright Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $167
    Market Newswire · 2026/8/10
  • Rating change
    J.P. Morgan Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Raises Target Price to $149
    Market Newswire · 2026/8/13
  • Rating change
    BMO Capital Maintains Protagonist Therapeutics(PTGX.US) With Buy Rating, Maintains Target Price $178
    Market Newswire · 2026/8/31

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-10-08 04:39:03 · For reference only, not investment advice and not tailored to your situation.